Medications

Tirzepatide improves kidney outcomes in T2DM with increased CV risk

An exploratory analysis of data from the SURPASS-4 trial has shown that adults with type 2 diabetes and increased cardiovascular risk receiving tirzepatide experience fewer renal complications, especially new onset of macroalbuminuria; ...

page 2 from 13